OncoCyte Corp 4
4 · OncoCyte Corp · Filed Feb 22, 2017
Insider Transaction Report
Form 4
HESTERBERG LYNDAL K.
Sr VP, Research & Development
Transactions
- Award
Option to Purchase Common Stock
2017-02-17+14,400→ 14,400 totalExercise: $4.70Exp: 2027-02-16→ Common Stock (14,400 underlying)
Holdings
- 25,000
Option to Purchase Common Stock
Exercise: $3.06Exp: 2026-02-15→ Common Stock (25,000 underlying) - 125,000
Option to Purchase Common Stock
Exercise: $4.05Exp: 2026-10-31→ Common Stock (125,000 underlying)
Footnotes (3)
- [F1]One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- [F2]One quarter of the options shall vest on October 31, 2017, subject to the completion of 12 months of continuous employment from the date of grant on November 1, 2016, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- [F3]One quarter of the options vested on February 15, 2017 and one quarter shall vest on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.